USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder

ChangeBridge: Patent Apps - Pharma (A61K)

Published September 22nd, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083736A1) filed on September 22, 2025, for novel ghrelin O-acyl transferase (GOAT) inhibitors. These compounds are designed for the treatment of substance use disorders (SUD), with a specific focus on opioid use disorder (OUD) and stimulant use disorder (StimUD) in individuals exhibiting high impulsivity. The application outlines compounds of general formula I and their therapeutic applications.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future developments in pharmaceutical research and development for SUD treatments. Companies involved in drug discovery and development in this therapeutic area should be aware of emerging intellectual property in this space.

Source document (simplified)

← USPTO Patent Applications

GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY

Application US20260083736A1 Kind: A1 Mar 26, 2026

Inventors

Stefan JUST, Hugo CRUCES SOLIS, Johann Faustus DU HOFFMANN, Jennifer Buenzle DWYER, Janet Rachel NICHOLSON, Katrin Hildegund PRELLER

Abstract

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.